Clinical Trials | February 16, 2026
Lundbeck’s bocunebart shows breakthrough potential in migraine prevention
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Glucon-D maintained its leadership position with a 59% MAT market share
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Subscribe To Our Newsletter & Stay Updated
